New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 14, 2014
10:00 EDTYELP, TDC, OPB, ZFGN, VNOM, AMTD, ZSPH, VRTV, PARN, ARDX, JMEI, FELP, SCHW, MRKT, ICPT, ETFC, CCS, MTSC, GBTZF, FANGOn The Fly: Analyst Initiation Summary
Today's noteworthy initiations include: Ardelyx (ARDX) initiated with a Buy at Citigroup... Century Communities (CCS) initiated with an Overweight at JPMorgan... Charles Schwab (SCHW) initiated with a Buy at Jefferies... Diamondback Energy (FANG) initiated with a Neutral at Sterne Agee... E-Trade (ETFC) initiated with a Hold at Jefferies... Foresight Energy (FELP) initiated with an Overweight at Morgan Stanley... Global Logistics Properties (GBTZF) initiated with an Overweight at Barclays... Intercept (ICPT) initiated with a Buy at Deutsche Bank... Jumei (JMEI) initiated with a Buy at BofA/Merrill... MTS Systems (MTSC) initiated with a Buy at Needham... Markit (MRKT) initiated with an Equal Weight at Morgan Stanley... Opus Bank (OPB) initiated with a Buy at CRT Capital... Parnell (PARN) initiated with an Overweight at Piper Jaffray... TD Ameritrade (AMTD) initiated with a Hold at Jefferies... Teradata (TDC) initiated with a Buy at Standpoint Research... Veritiv (VRTV) initiated with an Overweight at Barclays... Viper Energy (VNOM) initiated with a Market Perform at Raymond James... Yelp (YELP) initiated with an Underweight at Evercore... ZS Pharma (ZSPH) initiated with an Outperform at BMO Capital... Zafgen (ZFGN) initiated with an Outperform at Cowen.
News For ARDX;CCS;SCHW;FANG;ETFC;FELP;GBTZF;ICPT;JMEI;MTSC;MRKT;OPB;PARN;AMTD;TDC;VRTV;VNOM;YELP;ZSPH;ZFGN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
November 12, 2014
08:06 EDTYELPPacific Crest to hold a conference
Subscribe for More Information
07:36 EDTETFCE-Trade says to reduce corporate debt outstanding by $400M
Subscribe for More Information
07:28 EDTAMTDBofA/Merrill to hold a conference
Subscribe for More Information
November 11, 2014
16:15 EDTFANGDiamondback Energy files to sell 2M shares of common stock for holders
Credit Suisse Securities is acting as sole book-running manager for the offering.
16:11 EDTZFGNZafgen reports Q3 EPS (65c), consensus (87c)
As a result of increased clarity related to the timing of certain pre-clinical and clinical expenses, the company now expects to end 2014 with greater than $100M in cash and cash equivalents, as compared to the previous estimate of greater than $95M. "We are pleased to increase our cash guidance at the end of calendar year 2014 to greater than $100M from $95M in cash and cash equivalents," said Patricia Allen, Chief Financial Officer of Zafgen. "We believe this financial position enables us to continue to grow our business, including executing on and obtaining clinical data from three clinical trials we will be conducting in 2014 and 2015."
15:26 EDTYELPYelp continues to gain traction in Local search, says Cowen
Cowen's checks indicate Yelp (YELP) continues to gain traction in Local search through Google (GOOGL) and Facebook (FB). The firm continues to see Yelp's Local ad revenue growing 60% in 2014 and believes the company will continue to beat numbers.
12:00 EDTICPTIntercept results said to be rejected by New England Journal, Bloomberg says
Subscribe for More Information
10:00 EDTTDCOn The Fly: Analyst Initiation Summary
Subscribe for More Information
08:31 EDTAMTDTD Ameritrade reports October client trades up 17% from September
Subscribe for More Information
07:20 EDTTDCTeradata initiated with an Underperform at Macquarie
Subscribe for More Information
07:06 EDTMRKTMarkit Genpact KYC Services registers 600+ firms, appoints CEO
Markit Genpact KYC Services, the joint venture from Markit Ltd. (MRKT) and Genpact Ltd. (G) announced that more than 600 buyside firms and corporations are registered for its centralized service to streamline the management of know your customer information required by banks. Markit Genpact KYC Services also announced the appointment of Jon May as CEO. He joins Markit Genpact KYC Services from Goldman Sachs (GS) where he was a managing director and global head of client onboarding as well as head of Securities Operations and Operations Data Quality Management in India. Jon May will join Markit Genpact KYC Services in January 2015, based in London.
November 10, 2014
17:21 EDTMTSCMTS Systems sees FY15 EPS $3.60-$4.00, consensus $3.79
Subscribe for More Information
17:20 EDTMTSCMTS Systems reports Q4 EPS 71c, consensus 74c
Subscribe for More Information
16:04 EDTZSPHZS Pharma reports Q3 EPS (81c), consensus (74c)
Subscribe for More Information
09:41 EDTMRKTMarkit management to meet with JPMorgan
Subscribe for More Information
08:36 EDTICPTIntercept price target lowered to $125 from $172 at FBR Capital
FBR Capital lowered its price target for Intercept shares to $125 saying its talks with experts and cardiologists indicate the company's OCA drug is unlikely to be a "silver bullet" for the treatment of nonalcoholic steatohepatitis. FBR notes that while OCA appears to improve the liver, the drug worsens many of the other derangements like lipid and glucose homeostasis. FBR decreased the probability of success in NASH to 55% from 60%, and lowered its peak OCA sales estimate to $5.2B. It keeps an Underperform rating on Intercept shares.
07:23 EDTYELPRBC Capital to hold a conference
Subscribe for More Information
07:07 EDTCCSCentury Communities announces 2M stock repurchase program
Subscribe for More Information
06:51 EDTMRKTMarkit added to the short-term buy list at Deutsche Bank
Subscribe for More Information
November 9, 2014
11:56 EDTICPTIntercept announces additional data for OCA in primary biliary cirrhosis
Intercept Pharmaceuticals announced new analyses of data from clinical trials on obeticholic acid, OCA, in patients with primary biliary cirrhosis, PBC. Six posters, including posters with new analyses of data from POISE the first Phase 3 trial in PBC in two decades are being presented at today's poster session at the American Association for the Study of Liver Disease, AASLD, Annual Meeting. OCA, Intercept's lead product candidate, is a bile acid analog and first-in-class agonist of the farnesoid X receptor, FXR, in development for PBC, nonalcoholic steatohepatitis, NASH, primary sclerosing cholangitis, PSC, and other chronic liver diseases.
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use